To explore whether targeting the TFs mentioned above represents a therapeutic opportunity in GBM, we performed the pharmacological inhibition of AP‐1, RUNX1 and RUNX2 with the respective available chemical inhibitors T‐5224, Ro5‐3335 and CADD522. Here, FOS is linked to glioblastoma.